Using bioinformatics and artificial intelligence to map the cyclin-dependent kinase 4/6 inhibitor biomarker landscape in breast cancer

被引：1

作者：

Wager, Kim ^{[1
]}

Wang, Yao ^{[2
]}

Liew, Andrew ^{[1
]}

Campbell, Dean ^{[2
]}

Liu, Feng ^{[3
]}

Martini, Jean-Francois ^{[3
]}

Ziaee, Niusha ^{[2
]}

Liu, Yuan ^{[3
]}

机构：

[1] Oxford PharmaGenesis Ltd, AI & Data Sci, Oxford, England

[2] Pfizer Inc, Oncol Pfizer Biopharma, New York, NY 10001 USA

[3] Pfizer Inc, Pfizer Oncol Div, San Diego, CA 92121 USA

来源：

FUTURE ONCOLOGY | 2024年 / 20卷 / 40期

关键词：

artificial intelligence; bioinformatics; biomarkers; breast cancer; CDK4/6; inhibitors; drug resistance; HR+/HER2-; response; GROWTH-FACTOR; CDK4/6; INHIBITION; THERAPEUTIC RESPONSE; ENDOCRINE THERAPY; PLUS FULVESTRANT; PALBOCICLIB; RESISTANCE; CELLS; MECHANISMS; PHOSPHORYLATION;

D O I：

10.1080/14796694.2024.2419352

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

A cyclin-dependent kinase 4/6 (CDK4/6) inhibitor combined with endocrine therapy is the standard-of-care for patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer. However, not all patients respond to the treatment, resistance often occurs and efficacy outcomes from early breast cancer trials have been mixed. To identify biomarkers associated with CDK4/6 inhibitor response or resistance, we combined bioinformatic-database analyses, artificial intelligence-assisted literature review, and manual literature review (Embase and OVID Medline; search window: January 2012-October 2022) to compile data to comprehensively describe the CDK4/6 inhibitor biomarker landscape. Based on these results, and validation by external experts, we identified 15 biomarkers of clinical importance (AR,AURKA, ERBB2, ESR1, CCNE1, CDKN1A/B, CDK2, CDK6, CDK7, CDK9, FGFR1/2, MYC, PIK3CA/AKT, RB1 and STAT3) that could guide future breast cancer research.

引用

页码：3519 / 3537

页数：19

共 126 条

[1] The Development of a Selective Cyclin-Dependent Kinase Inhibitor That Shows Antitumor Activity [J].

Ali, Simak ;

Heathcote, Dean A. ;

Kroll, Sebastian H. B. ;

Jogalekar, Ashutosh S. ;

Scheiper, Bodo ;

Patel, Hetal ;

Brackow, Jan ;

Siwicka, Alekasandra ;

Fuchter, Matthew J. ;

Periyasamy, Manikandan ;

Tolhurst, Robert S. ;

Kanneganti, Seshu K. ;

Snyder, James P. ;

Liotta, Dennis C. ;

Aboagye, Eric O. ;

Barrett, Anthony G. M. ;

Coombes, R. Charles .

CANCER RESEARCH, 2009, 69 (15) :6208-6215

[2] High CDK6 Protects Cells from Fulvestrant-Mediated Apoptosis and is a Predictor of Resistance to Fulvestrant in Estrogen Receptor-Positive Metastatic Breast Cancer [J].

Alves, Carla L. ;

Elias, Daniel ;

Lyng, Maria ;

Bak, Martin ;

Kirkegaard, Tove ;

Lykkesfeldt, Anne E. ;

Ditzel, Henrik J. .

CLINICAL CANCER RESEARCH, 2016, 22 (22) :5514-5526

[3] Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2enegative advanced breast cancer: final overall survival results from SOLAR-1 [J].

Andre, F. ;

Ciruelos, E. M. ;

Juric, D. ;

Loibl, S. ;

Campone, M. ;

Mayer, I. A. ;

Rubovszky, G. ;

Yamashita, T. ;

Kaufman, B. ;

Lu, Y-S ;

Inoue, K. ;

Papai, Z. ;

Takahashi, M. ;

Ghaznawi, F. ;

Mills, D. ;

Kaper, M. ;

Miller, M. ;

Conte, P. F. ;

Iwata, H. ;

Rugo, H. S. .

ANNALS OF ONCOLOGY, 2021, 32 (02) :208-217

[4]

Andre F, 2020, J CLIN ONCOL, V38

[5]

[Anonymous], 2023, SEER Cancer Stat Facts: Ovarian Cancer

[6]

[Anonymous], 2023, FDA approves elacestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer

[7] The CDK4/6 inhibitors biomarker landscape: The most relevant biomarkers of response or resistance for further research and potential clinical utility [J].

Antonarelli, Gabriele ;

Salimbeni, Beatrice Taurelli ;

Marra, Antonio ;

Esposito, Angela ;

Locatelli, Marzia Adelia ;

Trapani, Dario ;

Pescia, Carlo ;

Fusco, Nicola ;

Curigliano, Giuseppe ;

Criscitiello, Carmen .

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2023, 192

[8] Modulation of Rb phosphorylation and antiproliferative response to palbociclib: the preoperative-palbociclib (POP) randomized clinical trial [J].

Arnedos, M. ;

Bayar, M. A. ;

Cheaib, B. ;

Scott, V. ;

Bouakka, I. ;

Valent, A. ;

Adam, J. ;

Leroux-Koza, V. ;

Marty, V. ;

Rapinat, A. ;

Mazouni, C. ;

Sarfati, B. ;

Bieche, I. ;

Balleyguier, C. ;

Gentien, D. ;

Delaloge, S. ;

Lacroix-Triki, M. ;

Michiels, S. ;

Andre, F. .

ANNALS OF ONCOLOGY, 2018, 29 (08) :1755-1762

[9] The history and future of targeting cyclin-dependent kinases in cancer therapy [J].

Asghar, Uzma ;

Witkiewicz, Agnieszka K. ;

Turner, Nicholas C. ;

Knudsen, Erik S. .

NATURE REVIEWS DRUG DISCOVERY, 2015, 14 (02) :130-146

[10] Systematic Review of Molecular Biomarkers Predictive of Resistance to CDK4/6 Inhibition in Metastatic Breast Cancer [J].

Asghar, Uzma S. ;

Kanani, Ruhi ;

Roylance, Rebecca ;

Mittnacht, Sibylle .

JCO PRECISION ONCOLOGY, 2022, 6

← 1 2 3 4 5 6 7 8 9 10 →